WO2003004045A3 - Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors - Google Patents

Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors Download PDF

Info

Publication number
WO2003004045A3
WO2003004045A3 PCT/CA2002/001016 CA0201016W WO03004045A3 WO 2003004045 A3 WO2003004045 A3 WO 2003004045A3 CA 0201016 W CA0201016 W CA 0201016W WO 03004045 A3 WO03004045 A3 WO 03004045A3
Authority
WO
WIPO (PCT)
Prior art keywords
wnt
methods
therapeutic agents
treating diseases
diseases involving
Prior art date
Application number
PCT/CA2002/001016
Other languages
French (fr)
Other versions
WO2003004045A2 (en
Inventor
Marcia L Macdonald
Yigal P Goldberg
Michael R Hayden
Original Assignee
Xenon Genetics Inc
Univ British Columbia
Marcia L Macdonald
Yigal P Goldberg
Michael R Hayden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Genetics Inc, Univ British Columbia, Marcia L Macdonald, Yigal P Goldberg, Michael R Hayden filed Critical Xenon Genetics Inc
Priority to AU2002317105A priority Critical patent/AU2002317105A1/en
Publication of WO2003004045A2 publication Critical patent/WO2003004045A2/en
Publication of WO2003004045A3 publication Critical patent/WO2003004045A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

Mutations in Wnt receptor genes, such as FZD4, associated with hereditary human visual disorders, such as familial exudative vitreoretinopathy ('FEVR'), are disclosed along with methods of use of Wnt and/or Wnt receptor genes and proteins, including in assays for therapeutic agents useful in treating such diseases and/or ameliorating their effects as well as methods of diagnosing diseases and disorders caused by mutations in these genes.
PCT/CA2002/001016 2001-07-05 2002-07-05 Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors WO2003004045A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002317105A AU2002317105A1 (en) 2001-07-05 2002-07-05 Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US30328501P 2001-07-05 2001-07-05
US60/303,285 2001-07-05
US34040901P 2001-10-29 2001-10-29
US60/340,409 2001-10-29
US36035202P 2002-02-28 2002-02-28
US60/360,352 2002-02-28

Publications (2)

Publication Number Publication Date
WO2003004045A2 WO2003004045A2 (en) 2003-01-16
WO2003004045A3 true WO2003004045A3 (en) 2003-05-30

Family

ID=27404928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001016 WO2003004045A2 (en) 2001-07-05 2002-07-05 Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors

Country Status (2)

Country Link
AU (1) AU2002317105A1 (en)
WO (1) WO2003004045A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
AU2003256079A1 (en) * 2002-08-30 2004-03-19 Japan As Represented By President Of The University Of Tokyo Method for treating synovial sarcoma
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
WO2005025590A2 (en) * 2003-09-15 2005-03-24 Develogen Aktiengesellschaft Use of a dg280 protein product for preventing and treating metabolic disorders
WO2006130076A1 (en) * 2005-05-30 2006-12-07 Astrazeneca Ab Methods for identifying fzd8 modulators and the use of such modulators for treating osteoarthritis
WO2007030658A2 (en) 2005-09-08 2007-03-15 Children's Hospital Medical Center Compositions useful for and methods of modulating angiogenesis
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
ES2618785T3 (en) 2005-10-31 2017-06-22 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating cancer based on human FZD receptors
CN101365945A (en) * 2006-02-07 2009-02-11 惠氏公司 Materials and methods for identifying agents that modulate norrin, norrin mimetics, and agents identified thereby
CA2655289C (en) 2006-06-21 2016-08-23 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to fzd10 and uses thereof
JP2010504081A (en) 2006-09-08 2010-02-12 ジェネンテック インコーポレイテッド Use of WNT antagonists and in the diagnosis and treatment of WNT-mediated disorders
CN105079805A (en) 2008-09-26 2015-11-25 昂考梅德药品有限公司 Frizzled-binding agents and uses thereof
EP2491143B1 (en) * 2009-10-21 2017-12-13 Retinal Solutions LLC Methods and compositions for diagnosis and treatment of genetic and retinal disease
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CN102971337B (en) 2010-04-01 2016-09-21 昂考梅德药品有限公司 FZ combines medicament and application thereof
AU2012271413B2 (en) 2011-06-17 2017-07-13 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
CN105073195A (en) 2013-02-04 2015-11-18 昂科梅德制药有限公司 Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI762516B (en) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 Monoclonal antibodies against FZD10 and their uses
CN111394453A (en) * 2020-05-11 2020-07-10 四川省人民医院 Primer group, kit and method for detecting FEVR-related pathogenic gene mutation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (en) * 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Wnt RECEPTOR COMPOSITIONS AND METHODS
WO1999026960A2 (en) * 1997-11-25 1999-06-03 Millennium Pharmaceuticals, Inc. Genes encoding frizzled-like proteins
EP1001023A2 (en) * 1998-09-09 2000-05-17 Smithkline Beecham Plc Frizzled-4, a putative Wnt-receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (en) * 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Wnt RECEPTOR COMPOSITIONS AND METHODS
WO1999026960A2 (en) * 1997-11-25 1999-06-03 Millennium Pharmaceuticals, Inc. Genes encoding frizzled-like proteins
EP1001023A2 (en) * 1998-09-09 2000-05-17 Smithkline Beecham Plc Frizzled-4, a putative Wnt-receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIRIKOSHI H ET AL: "MOLECULAR CLONING AND CHARACTERIZATION OF HUMAN FRIZZLED-4 ON CHROMOSOME 11Q14-Q21", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 264, no. 3, 2 November 1999 (1999-11-02), pages 955 - 961, XP001057078, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2003004045A2 (en) 2003-01-16
AU2002317105A1 (en) 2003-01-21

Similar Documents

Publication Publication Date Title
WO2003004045A3 (en) Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
ATE353013T1 (en) TRICYCLIC PYRAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTITUMOR AGENTS
DE69922261D1 (en) MONOCLONAL ANTIBODIES, ANTIGENS AND DIAGNOSIS AND THERAPY OF VICIOUS DISEASES
WO2002067760A3 (en) Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
HK1112941A1 (en) Use of a33 antigens and jam-it a33
WO2006125830A3 (en) Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases
WO2001064877A3 (en) Human schizophrenia gene
AU9363398A (en) Hepatitis c receptor protein cd81
WO2004039940A3 (en) Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
WO2001017558A3 (en) Novel uses of mammalian ccr6 receptors and related reagents
WO2002083856A3 (en) Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof
WO2000078795A3 (en) Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1)
WO2004100886A3 (en) POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-kB PATHWAY
WO2003005034A3 (en) Processes for identifying therapeutic agents useful in treating diseases involving fzd4 gene
WO2004083241A3 (en) Btc-interacting proteins and use thereof
NO993653D0 (en) Procedure for diagnosis, prognosis and treatment of glaucoma and related diseases
BR9908443A (en) Human spinal cord cell lines and methods for using them
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
ATE495269T1 (en) ADARB2 PROTEINS AS DIAGNOSTIC AND THERAPEUTIC TARGETS FOR NEURODEGENERATIVE DISEASES
DE602004025936D1 (en) THERAPEUTIC COMPOSITION CONTAINING DENTRITIC CELLS AND THEIR USE
WO2006029838A3 (en) Secreted polypeptide species involved in alzheimer’s disease
WO2001058484A3 (en) Novel uses of mammalian ccr8 receptors and related reagents
WO2003039327A3 (en) Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP